L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

(2014) Evguenia S. Svarovskaia et al.   CLINICAL INFECTIOUS DISEASES

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

(2014) Eric F. Donaldson et al.   HEPATOLOGY

P1303 AN INTERFERON- AND RIBAVIRIN-FREE 12-WEEK REGIMEN OF ONCE-DAILY VX-135 AND DACLATASVIR IN TREATMENT-NAÏVE PATIENTS WITH GENOTYPE 1 HCV INFECTION

(2014) E. Gane et al.   JOURNAL OF HEPATOLOGY

Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study

(2014) Edward J. Gane et al.   LIVER INTERNATIONAL

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

(2014) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir

(2013) Xiao Tong et al.   JOURNAL OF INFECTIOUS DISEASES

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

(2013) Kris V Kowdley et al.   LANCET

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

(2013) Eric Lawitz et al.   LANCET

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

(2013) Eric Lawitz et al.   LANCET INFECTIOUS DISEASES

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

(2013) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

(2013) Edward J. Gane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus

(2012) Angela M. Lam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial

(2012) Maribel Rodriguez-Torres et al.   JOURNAL OF HEPATOLOGY

PSI-7851, a Pronucleotide of  -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication

(2010) A. M. Lam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

(2010) Michael J. Sofia et al.   JOURNAL OF MEDICINAL CHEMISTRY